Echezona E Ezeanolue1, Chidi Nwizu, Gregory S Greene, Olatilewa Amusu, Chinwe Chukwuka, Nicaise Ndembi, Rachel M Smith, Tom Chiller, Jennifer Pharr, Thomas R Kozel. 1. *Global Health Initiative, School of Community Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; †Department of Pediatrics, University of Nevada School of Medicine, Las Vegas, NV; ‡Centre for Clinical Care and Clinical Research, Nigeria (CCCRN), Abuja, Nigeria; §Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA; ‖Nigerian Army Reference Hospital, Lagos, Nigeria; ¶Department of Medicine, College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria; #Institute of Human Virology Nigeria, Abuja, Nigeria; and **Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV.
Abstract
OBJECTIVE: Worldwide, HIV-associated cryptococcal meningitis affects approximately 1 million persons and causes 600,000 deaths each year mostly in sub-Saharan Africa. Limited data exist on cryptococcal meningitis and antigenemia in Nigeria, and most studies are geographically restricted. We determined the prevalence of cryptococcal antigenemia (CrAg) among HIV-infected, treatment-naive individuals in Nigeria. DESIGN/ METHODS: This was a retrospective, cross-sectional study across 4 geographic regions in Nigeria. We performed CrAg testing using a lateral flow immunoassay on archived whole-blood samples collected from HIV-infected participants at US President's Emergency Plan for AIDS Relief (PEPFAR)-supported sites selected to represent the major geographical and ethnic diversity in Nigeria. Eligible samples were collected from consenting patients (>15 years) naive to antiretroviral therapy with CD4 count less than 200 cells per cubic millimeter and were stored in an -80°C freezer. RESULTS: A total of 2752 stored blood samples were retrospectively screened for CrAg. Most of the samples were from participants aged 30-44 years (57.6%), and 1570 (57.1%) were from women. The prevalence of CrAg positivity in specimens with CD4 <200 cells per cubic millimeter was 2.3% (95% confidence interval: 1.8% to 3.0%) and varied significantly across the 4 regions (P < 0.001). At 4.4% (3.2% to 5.9%), the South East contained the highest prevalence. CONCLUSIONS: The significant regional variation in CrAg prevalence found in Nigeria should be taken into consideration as plans are made to integrate routine screening into clinical care for HIV-infected patients.
OBJECTIVE: Worldwide, HIV-associated cryptococcal meningitis affects approximately 1 million persons and causes 600,000 deaths each year mostly in sub-Saharan Africa. Limited data exist on cryptococcal meningitis and antigenemia in Nigeria, and most studies are geographically restricted. We determined the prevalence of cryptococcal antigenemia (CrAg) among HIV-infected, treatment-naive individuals in Nigeria. DESIGN/ METHODS: This was a retrospective, cross-sectional study across 4 geographic regions in Nigeria. We performed CrAg testing using a lateral flow immunoassay on archived whole-blood samples collected from HIV-infectedparticipants at US President's Emergency Plan for AIDS Relief (PEPFAR)-supported sites selected to represent the major geographical and ethnic diversity in Nigeria. Eligible samples were collected from consenting patients (>15 years) naive to antiretroviral therapy with CD4 count less than 200 cells per cubic millimeter and were stored in an -80°C freezer. RESULTS: A total of 2752 stored blood samples were retrospectively screened for CrAg. Most of the samples were from participants aged 30-44 years (57.6%), and 1570 (57.1%) were from women. The prevalence of CrAg positivity in specimens with CD4 <200 cells per cubic millimeter was 2.3% (95% confidence interval: 1.8% to 3.0%) and varied significantly across the 4 regions (P < 0.001). At 4.4% (3.2% to 5.9%), the South East contained the highest prevalence. CONCLUSIONS: The significant regional variation in CrAg prevalence found in Nigeria should be taken into consideration as plans are made to integrate routine screening into clinical care for HIV-infectedpatients.
Authors: Sara A Mirza; Maureen Phelan; David Rimland; Edward Graviss; Richard Hamill; Mary E Brandt; Tracie Gardner; Matthew Sattah; Gabriel Ponce de Leon; Wendy Baughman; Rana A Hajjeh Journal: Clin Infect Dis Date: 2003-02-27 Impact factor: 9.079
Authors: J G Hakim; I T Gangaidzo; R S Heyderman; J Mielke; E Mushangi; A Taziwa; V J Robertson; P Musvaire; P R Mason Journal: AIDS Date: 2000-07-07 Impact factor: 4.177
Authors: David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2010-08-15 Impact factor: 9.079
Authors: Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Rachel M Smith; Tuan Anh Nguyen; Hoang Thi Thanh Ha; Pham Hong Thang; Cao Thuy; Truong Xuan Lien; Hien T Bui; Thai Hung Le; Bruce Struminger; Michelle S McConnell; Robyn Neblett Fanfair; Benjamin J Park; Julie R Harris Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240
Authors: Joseph N Jarvis; Thomas S Harrison; Stephen D Lawn; Graeme Meintjes; Robin Wood; Susan Cleary Journal: PLoS One Date: 2013-07-19 Impact factor: 3.240
Authors: Kinanga A Magambo; Samuel E Kalluvya; Shikha W Kapoor; Jeremiah Seni; Awilly A Chofle; Daniel W Fitzgerald; Jennifer A Downs Journal: J Int AIDS Soc Date: 2014-08-08 Impact factor: 5.396
Authors: Iorhen E Akase; Olamide Olowoyo; Rita O Oladele; Reginald O Obiako; Adilia Warris; Sulaimon A Akanmu Journal: Med Mycol Case Rep Date: 2019-04-16
Authors: Nathan Ford; Zara Shubber; Joseph N Jarvis; Tom Chiller; Greg Greene; Chantal Migone; Marco Vitoria; Meg Doherty; Graeme Meintjes Journal: Clin Infect Dis Date: 2018-03-04 Impact factor: 9.079